



BioSyent Inc.  
Q1 2026 Results  
MAY 14, 2026

PRESENTED BY: RENÉ GOEHRUM  
PRESIDENT AND CEO



## DISCLAIMER

This presentation is for informational purposes only and should not be considered as an offer to buy or sell securities. No stock exchange has either approved or disapproved of the information that is contained in this presentation. This presentation may contain forward-looking statements within the meaning of Canadian Securities legislation and the forward-looking statements contained herein are made as at the date of this presentation and, accordingly, are subject to change after such date. Undue reliance should not be placed on such statements. These statements involve a number of risks and uncertainties including statements regarding the outlook for BioSyent Inc., business and operational results.

By nature, these risks and uncertainties could cause actual results to differ materially from what has been indicated. Factors that could cause actual results to differ materially from any forward-looking statement include, but are not limited to, failure to obtain governmental regulatory approvals, product recalls, competition from similar products and other factors including those risks and uncertainties identified above.

BioSyent Inc. undertakes no obligation to update publicly or otherwise revise any forward-looking information as a result of new information, future results or other such factors which affect this information, except as required by law.



# Acquisition of Oral Science



## Acquisition of Privately-Owned Canadian Distributor of Specialized Healthcare Products for Dental Hygiene and Oral Health

- Share Purchase Agreement (SPA) closed on March 1, 2026
- Purchase price of \$25.5M (including \$6.3M working capital)
  - + \$2.0M paid for excess working capital
  - + performance earn out
  - + royalties on future sales of 1 product
- Purchase price and FY 2025 financial results of Oral Science implies <6x EBITDA purchase multiple
- Founders and key management of Oral Science now shareholders of BioSyent (234,192 shares / ~2% of RX issued shares)
- Oral Science will continue to operate as stand-alone Oral Health Business of BioSyent
- Oral Science leadership continues to lead the Oral Health Business





RepaGyn®

FLORIDA PROBE  
VoiceWorks

Cathejell®



inofolic®

**GENGIGEL®**  
0.2% HYALURONIC ACID TOPICAL GEL



Cetacaine®



**Tibella®**  
Tibelia Global

Advantage  
Arrest™

Proktis-M®

**CURAPROX**  
+ SWISS PREMIUM ORAL CARE



**HYBENX®**

# Oral Science Overview



Growing, revenue-stage oral health company with a successful track record of developing, sourcing, marketing and distributing innovative dental hygiene and oral health products

- Founded in 2003
- Based in Brossard, Quebec, Canada with a national salesforce
- Revenue base:
  - 1/3 of sales from proprietary products and technologies
  - 2/3 of sales from in-licensed products

## Full Year 2025 Annual Financial Results (ASPE)


- Revenues: \$31.2M
- NIBT: \$ 4.3M

2018 – 2025 Revenue CAGR > 15%

## March 2026 Monthly Financial Results (IFRS)

- Revenues: ~\$3.0M
- EBITDA<sup>(1)</sup>: ~\$0.5M

# ProForma 2025 Revenue and EBITDA: BioSyent + Oral Science



Annual Revenue - BioSyent

BioSyent 2025 EBITDA	Oral Science 2025 EBITDA (ASPE)	Combined ProForma 2025 EBITDA
\$12.1M	\$4.4M	\$16.5M

# Oral Science Overview



## Provisional Purchase Price Allocation (IFRS 3 – Business Combinations)\*

\*Subject to change

Provisional Purchase Price Allocation	Amount
Working capital	\$8,307,534
Property and equipment	791,813
Intangible assets	17,426,010
Goodwill	3,750,000
Lease liability	(475,357)
<u>Net assets acquired</u>	<u>\$29,800,000</u>

### March 2026

- \$250k amortization expense on acquired intangible assets
- \$273k one-time transaction closing expenses

# Q1 2026 Sales Summary (\$)

(CAD 000's)	Q1 '26 Sales	Q1 '25 Sales	Q1 '26 vs. Q1 '25 (%)
Pharmaceutical	10,803	10,695	+1%
Oral Health	2,985	-	n/a
Insecticides	120	284	(58%)
<b>Total Company</b>	<b>13,908</b>	<b>10,979</b>	<b>+27%</b>


Canadian Pharma Sales **+9%**  
 International Pharma Sales **(44%)\***

\*Shipment of Tibelia Intn'l order backlog in Q1 2025

One month of post-acquisition sales generated by Oral Health segment


# Sales, EBITDA and NIAT

## Quarter ended March 31<sup>st</sup> (Q1)




# Sales, EBITDA and NIAT

## Quarter ended March 31<sup>st</sup> (Q1)




# Fully Diluted Earnings per Share (TTM)



Earnings Growth + NCIB Share Buybacks Drive EPS Growth

# Fully Diluted Earnings per Share (TTM)




Earnings Growth + NCIB Share Buybacks Drive EPS Growth

# Other 2026 Highlights



- Apr 2026: FeraMAX<sup>®</sup> named #1 recommended iron supplement in Canada for **eleventh** consecutive year
- YTD Mar 31, 2026: 100,000 shares repurchased and cancelled under NCIB
- Mar 13, 2026: Paid quarterly dividend of \$0.055/share (+10% increase vs. 2025)
- May 14, 2026: Declared quarterly dividend of \$0.055/share payable on June 15, 2026



# FeraMAX®



- Most recommended iron supplement in Canada - pharmacists and physicians - **11** consecutive years<sup>(1)</sup>
- Continued innovation and expansion of FeraMAX® product line for iron health

*(1) Based on Pharmacy Practice + Business, The Medical Post and Profession Santé 2026 Survey on OTC Counselling and Recommendations*

# Geopolitics, Trade and Economy


---

- Uncertainty
- Armed conflicts
- Tariffs / Counter-Tariffs
- Inflationary impacts
  - Transportation
  - Supply Chains
  - Cost of Goods
  - Consumer Behaviour



# Cash Balance & Return on Equity (“RoE”)

March 31, 2026



- Q1 2026 Cash from Operations; **\$2.7M**
- Q1 2026 NCIB share buybacks: **\$1.4M**
- Q1 2026 Net Dividends: **\$0.6M**
- Q1 2026 Net Debt Proceeds: **\$4.0M**
- **(\$22.2M)** Net Cash deployed in Oral Science acquisition Mar 2026
- Execution of strategy drives TTM RoE of **22%**

# Strong Balance Sheet + Cash Generation

## Supports Ongoing Portfolio Opportunities


(CAD 000,000's)	Dec 31, 2025	Mar 1, 2026 (Acquisition Closing Date)	Mar 31, 2026
Cash and GICs	31.9	17.2	14.2
Non-cash Working Capital	4.0	8.5	7.8
Non-current Assets	6.4	27.9	27.9
(Short Term Debt) <sup>(1)</sup>	-	(8.0)	(4.0)
(Non-current Liabilities)	(0.8)	(0.9)	(0.9)

(1) Short term debt to be fully repaid Sept 30, 2026



# Capital Allocation linked to Strategy

First use of capital is to generate revenue/profit growth & portfolio diversification.



- 7 new product launches in Canada since July 2020
- Cash deployed in acquisitions
  - \$ 4.2 M Tibelia® / Tibella® (tibolone) Acquisition of global rights Sept 2024
  - \$22.2 M Oral Science Acquisition Mar 2026

# Stock Information

As at May 12, 2026

Exchange & Trading Symbol	TSXV: RX
May 12, 2026 Closing Stock Price (CAD) (TSXV):	\$14.65
52 Week Hi/Low (TSXV):	\$15.80 / \$10.65
Issued Common Shares:	11,617,145
Treasury – RSU Shares in Trust	(178,827)
Outstanding Common Shares:	11,438,318
Options Outstanding	90,170
RSUs Outstanding	<u>207,189</u>
Fully Diluted Common Shares:	<u>11,735,677</u>
P/E Ratio :	18.51
EV/EBITDA <sup>(1)</sup> (TTM):	12.88
EV/EBITDA <sup>(1)</sup> (ProForma 2025 – see Slide 6):	9.81



- ✓ WELL CAPITALIZED.
- ✓ PROFITABLE.
- ✓ GROWTH ASSETS.
- ✓ COMPOUNDING TRACK RECORD.
- ✓ FOCUSED ON LONG-TERM GROWTH AND TOTAL SHAREHOLDER RETURN.



# Reconciliation of EBITDA to NIAT

1. **EBITDA** is a Non-IFRS Financial Measure. The term EBITDA does not have any standardized meaning under International Financial Reporting Standards (IFRS) and therefore may not be comparable to similar measures presented by other companies. The Company defines EBITDA as earnings before interest income or expense, income taxes, depreciation and amortization.

A reconciliation of EBITDA to NIAT for the three months ended March 31, 2026 and 2025 is provided in the table below:

	First Quarter (Q1) Ended March 31	
	2026	2025
<b>EBITDA</b>	<b>3,639,086</b>	<b>3,201,647</b>
Add: Interest Income	166,792	179,010
Less:		
Depreciation - Property, Equipment	(94,112)	(66,907)
Amortization of Intangible Assets	(394,849)	(144,276)
Interest Expense	(31,616)	(13,103)
Income Tax Expense	(940,482)	(836,438)
<b>NIAT</b>	<b>2,344,819</b>	<b>2,319,933</b>